- Home
- BRN vs NRSN Comparison
BRN vs NRSN Comparison
Compare BRN & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRN | NRSN |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 26.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRN | NRSN |
|---|---|---|
| Price | $1.13 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 56.5K | ★ 335.2K |
| Earning Date | 12-19-2025 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,073,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.05 | $0.76 |
| 52 Week High | $2.28 | $2.60 |
Technical Indicators
Market Signals| Indicator | BRN | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 30.92 |
| Support Level | $1.10 | $0.76 |
| Resistance Level | $1.19 | $0.91 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 50.00 | 0.08 |
Price Performance
Historical ComparisonAbout BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.